Physician profile
Christopher Laninga
NPI 1508481235
$4,360.09
in general payments reported to CMS, 2019-2025
25 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $755 · 2022: $1,191 · 2023: $1,055 · 2024: $993 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,414.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,065.70 | 2021-2024 | |
| Glaxosmithkline, LLC. | $760.67 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $686.63 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $472.73 | 2022-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $164.09 | 2021-2024 | Zepbound |
| Bard Peripheral Vascular, INC. | $141.48 | 2023 | Venovo |
| E.R. Squibb & Sons, L.L.C. | $134.27 | 2023 | Camzyos |
| Idorsia Pharmaceuticals US INC | $131.26 | 2022 | |
| Axsome Therapeutics, INC. | $124.99 | 2024 | Auvelity |
| Philips North America LLC | $98.19 | 2023 | |
| Amgen INC. | $83.57 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $79.06 | 2021-2024 | Spravato |
| Aimmune Therapeutics, INC. | $61.27 | 2025 | Zenpep |
| Bayer Healthcare Pharmaceuticals INC. | $46.73 | 2022 | |
| Dexcom, INC. | $44.90 | 2022-2023 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $40.96 | 2024-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $38.22 | 2021-2022 | |
| Astellas Pharma US INC | $34.80 | 2021-2024 | Veozah |
| Pfizer INC. | $33.77 | 2021 | |
| Merck Sharp & Dohme LLC | $32.95 | 2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Otsuka America Pharmaceutical, INC. | $22.88 | 2022 | |
| Neurocrine Biosciences, INC. | $17.80 | 2022 | |
| Alkermes, INC. | $16.45 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.79 | 2024 | Zoryve |
| Boston Scientific Corporation | $12.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Laninga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.